… most innovative and promising private biotechnology companies in the industry. … report has spotlighted the private biotechs pushing science into uncharted … About Fierce Biotech Fierce Biotech covers the biopharma waterfront, from drug development through …

… adding that Food and Drug Administration (FDA) Commissioner Marty … “Enhancing U.S. Biotechnology Security within the Houston … can maintain its global biotech leadership. Topics ranged from … the national conversation on biotechnology security and growth.” iC3 …

… polypharmacy may lead to unforeseen drug-drug interactions (DDIs), potentially compromising … were purchased from Hubei Yizhicheng Biotechnology Co., Ltd. The experiment … . In terms of pharmacodynamics, drugs used in combination with dexmedetomidine …

… nearly 43% premium to the biotech company's Friday… develop its own lead obesity drug candidate, danuglipron, before deciding … also includes a monthly drug targeting a hormone called … said Metsera's experimental drugs "should accelerate" …

… handful of experimental weight-loss drugs, including a shot that could … often than the market-leading drugs from Eli Lilly & … gentler option to GLP-1 drugs like Wegovy and Zepbound, … to license another amylin drug from Danish biotech Zealand Pharma A…

… fast-growing weight-loss drug market. According to sources … its own experimental weight-loss drug, danuglipron, failed in clinical … billion purchase of cancer-focused biotech Seagen in 2023. Metsera, … therapies, as well as drugs that harness the hormone amylin …

… year became the first novel drug for schizophrenia in more than … months-long IPO drought. The biotech initially aimed for a $263 …

… Partnering with the most innovative biotech and pharmaceutical companies worldwide, Biognosys … next-generation proteomics to accelerate drug discovery and development, and … types into actionable biomarkers, accelerated drug development, and more precise …

Belgian biotech company Argenx is joining the … spark new interest in the biotech sector, which has long been … rare conditions. Sales of the drug in the second quarter of …

… drug candidate in late 2023 when it acquired U.S. biotech … dominant makers of weight-loss drugs Novo Nordisk and Eli … an update on its obesity drugs pipeline at an investor … new therapeutic areas with competitive drugs that became blockbusters. (Reporting …